TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37823034
Drug: Diluted TV-46046
Normalized name: phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diluted TV-46046 (60 mg/0.3 mL)
Study: 37823034
Drug: TV-46046 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TV-46046 placebo (0.3 mL)
Study: 37823722
Drug: Fingolimod treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod treatment
Study: 37823971
Drug: Heparin (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (5000 IU/ml)
Study: 37824131
Drug: Intratumoral GLA-SE
Normalized name: Selenomethionine Se-75
DrugBank: Selenomethionine Se-75 (DB09400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral GLA-SE (5 μg and 10 μg for 8 weekly doses) with concurrent radiotherapy
Study: 37824131
Drug: Intratumoral GLA-SE
Normalized name: Selenomethionine Se-75
DrugBank: Selenomethionine Se-75 (DB09400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral GLA-SE with concurrent radiotherapy
Study: 37824137
Drug: Topotecan alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan alone (1.25 mg/m2 intravenously on days 1 through 5)
Study: 37824137
Drug: Topotecan with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan with berzosertib (210 mg/m2 intravenously on days 2 and 5)
Study: 37824155
Drug: Cryoprecipitate (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryoprecipitate (3 pools, 6-g fibrinogen equivalent) administered within 90 minutes of randomization and 3 hours of injury, in addition to standard care.
Study: 37824754
Drug: Art Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Art Therapy
Study: 37826937
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg caffeine
Study: 37826937
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg caffeine
Study: 37827268
Drug: Cabergoline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (1 mg once on postpartum day 1 or 0.25 mg twice a day for 2 days)
Study: 37827268
Drug: Pyridoxine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxine (200 mg 3 times a day for 7 days)
Study: 37827280
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose and treatment volume
Study: 37827744
Drug: Patient-led home-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-led home-based surveillance after curative CRC treatment.
Study: 37828033
Drug: Sintilimab (anti-PD-1)
Normalized name: Dianeal PD-2/1.5
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab (anti-PD-1) at doses of 1, 3, and 10 mg/kg
Study: 37828034
Drug: ZSP1601 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP1601 50 mg once daily
Study: 37828034
Drug: ZSP1601 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP1601 50 mg twice daily
Study: 37828034
Drug: ZSP1601 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP1601 100 mg twice daily
Study: 37828071
Drug: Diabetes mellitus
Normalized name: diagnostic,monitoring agents for diabetes mellitus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes mellitus severity and treatment regimen (oral medication vs insulin vs both oral + insulin)
Study: 37828071
Drug: LDL <
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LDL < 100 mg/dl
Study: 37828470
Drug: Clinical assessment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical assessment, chest X-ray, and comprehensive lung function assessment at treatment completion and again six and 12 months later.
Study: 37828564
Drug: Group Physical
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Physical Therapy Program for Knee OA (Group PT) with tailored, high-touch support (enREP)
Study: 37828564
Drug: Group Physical
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Physical Therapy Program for Knee OA (Group PT) with standard, low-touch support (REP)
Study: 37828618
Drug: Enhanced therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced therapy (personalized treatment approach including pressure-optimized custom-made footwear, at-home daily foot temperature monitoring, structured education)
Study: 37830579
Drug: Mitazalimab (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitazalimab (600 µg/kg and 900 µg/kg administered intravenously)
Study: 37830908
Drug: mRNA-1273 (Moderna)
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine
Study: 37831074
Drug: Continuous anti-IL-6R
Normalized name: Anti-IL-20
DrugBank: Fletikumab (DB12356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous anti-IL-6R therapy
Study: 37831433
Drug: New prognostic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New prognostic model based on four variables: past deterioration, neutrophil proportion > 70%, Na < 128 mmol/L, and vasopressor use.
Study: 37831485
Drug: Motivational Interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Interviewing (MI) intervention focusing on PrEP use and concomitant stimulant use or CAS
Study: 37832758
Drug: Allopurinol 300
Normalized name: allopurinol 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 300 mg once daily for 6 months
Study: 37833472
Drug: Hydromorphone 2
Normalized name: HYDROmorphone 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone 2 mg given six hours after interscalene block
Study: 37833472
Drug: Hydromorphone 2
Normalized name: HYDROmorphone 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone 2 mg and Placebo
Study: 37833493
Drug: HSK21542 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK21542 (2 μg/0.212 μCi/kg)
Study: 37833679
Drug: Liberalized potassium
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberalized potassium diet (3500 mg dietary K daily)
Study: 37833679
Drug: Standard potassium
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard potassium restricted diet (<2000 mg dietary K daily)
Study: 37834761
Drug: Tegoprazan 50
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan 50 mg daily
Study: 37835071
Drug: Immunoadsorption (IA)
Normalized name: magnesium aluminum silicate type Ia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoadsorption (IA) combined with B-cell depletion therapy
Study: 37837376
Drug: Immunotherapy regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy regimen during ATI
Study: 37837942
Drug: Treatment strategies
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment strategies at t0 (time of active suicidal ideation with intent)
Study: 37837989
Drug: Endovascular thrombectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular thrombectomy with medical treatment
Study: 37837989
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment alone (standard of care)
Study: 37838323
Drug: Small-bowel capsule
Normalized name: Smallpox (Vaccinia) Vaccine, Live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-bowel capsule endoscopy (SB-CE)
Study: 37838604
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (1000 mg i.v. administered 24-72 hours before surgery)
Study: 37838604
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered 24-72 hours before surgery)
Study: 37838623
Drug: SHR7280 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR7280 (200 mg QD, 300 mg QD, 200 mg BID)
Study: 37838686
Drug: Handgrip strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Handgrip strength (HGS) during chemotherapy
Study: 37838686
Drug: Minnesota Manual
Normalized name: influenza A virus A/Minnesota/41/2019 (H3N2) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minnesota Manual Dexterity Test (MMDT) during chemotherapy
Study: 37838686
Drug: European Organization
Approvals — FDA: no, EMA: no, PMDA: no
Description: European Organization for Research and Treatment of Cancer Quality of Life Module Cancer Related Fatigue (EORTC-QLQ-FA12) during chemotherapy
Study: 37838686
Drug: Semmes Weinstein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semmes Weinstein Monofilament Test (SWMT) during chemotherapy
Study: 37838987
Drug: Trifarotene 50
Normalized name: Trifarotene 50 microgram/g cutaneous cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifarotene 50 μg/g
Study: 37839707
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (400 mg/d)
Study: 37839958
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy (MBCT) - 10 weekly sessions of 120 minutes each
Study: 37840119
Drug: Spesolimab (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spesolimab (900 mg, single intravenous dose on day 1)
Study: 37840134
Drug: sarilumab 200
Normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: sarilumab 200 mg (SAR200 + 26W)
Study: 37840134
Drug: sarilumab 150
Normalized name: SARILUMAB 150MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: sarilumab 150 mg (SAR150 + 26W)
Study: 37840134
Drug: placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo with 52-week GC taper (PBO + 52W)
Study: 37840134
Drug: placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo with 26-week GC taper (PBO + 26W)
Study: 37840155
Drug: Danuglipron (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danuglipron (20 mg)
Study: 37840530
Drug: Abemaciclib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib monotherapy
Study: 37840530
Drug: SOC chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC chemotherapy (gemcitabine or capecitabine)
Study: 37840766
Drug: 1.5% ruxolitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% ruxolitinib cream applied to lesions once or twice daily for 52 weeks
Study: 39418346
Drug: Palbociclib plus
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib plus an aromatase inhibitor (AI)
Study: 37842323
Drug: shen-based qigong
Approvals — FDA: no, EMA: no, PMDA: no
Description: shen-based qigong exercise intervention along with daily rehabilitation
Study: 37842323
Drug: daily rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily rehabilitation
Study: 37843771
Drug: Tirzepatide 5
Normalized name: tirzepatide 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide 5 mg, 10 mg, 15 mg
Study: 37843843
Drug: Resveratrol supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol supplementation (400 mg/d for 6 weeks)
Study: 37844137
Drug: SAVAL self-expandable
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SAVAL self-expandable paclitaxel drug-eluting stent (DES)
Study: 37844597
Drug: Nivolumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab monotherapy (240 mg IV every 2 weeks)
Study: 37844597
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus ipilimumab (3 mg/kg and 1 mg/kg respectively) boosts
Study: 37844598
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg intravenous once every 3 weeks plus lenvatinib 20 mg oral once per day for up to 2 years or until disease progression, development of unacceptable toxicity, or withdrawal of consent.
Study: 37844986
Drug: OCA group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCA group (oxycodone: 0.5 mg/kg)
Study: 37844986
Drug: OCB group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCB group (oxycodone: 1.0 mg/kg)
Study: 37844986
Drug: OCC group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCC group (oxycodone: 1.5 mg/kg)
Study: 37844986
Drug: Sufentanil group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil group (sufentanil: 2 µg/kg)
Study: 37844986
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (including flurbiprofen 50 mg and ondansetron 16 mg)
Study: 37845427
Drug: Idarucizumab (2×2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarucizumab (2×2.5 g/50 ml) in group A
Study: 37845427
Drug: Idarucizumab (2×2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarucizumab (2×2.5 g/50 ml) in group B
Study: 37845511
Drug: Nivolumab 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 480 mg every 4 weeks for 12 months
Study: 37845511
Drug: Nivolumab 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 480 mg
Study: 38324483
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg resmetirom
Study: 38324483
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg resmetirom
Study: 37845512
Drug: Open-label 100
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label 100 mg resmetirom
Study: 37845608
Drug: Adjuvanted recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted recombinant glycoprotein E subunit herpes zoster vaccine (RZV)
Study: 37845612
Drug: Oropharyngeal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oropharyngeal administration of 0.2 ml colostrum every 3 hours for 5 consecutive days.
Study: 37845612
Drug: Oropharyngeal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oropharyngeal administration of sterile water (control group).
Study: 37845696
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy (pemetrexed plus cisplatin/carboplatin, C)
Study: 37846080
Drug: Investigator-chosen chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator-chosen chemotherapy (paclitaxel, docetaxel, or irinotecan)
Study: 37846462
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (0.5 and 1.0 mg/kg)
Study: 37846724
Drug: TAK-003 (Qdenga®),
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-003 (Qdenga®), a live attenuated dengue tetravalent vaccine, administered during the second half of its 24-month shelf-life
Study: 37846845
Drug: Early relapse
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early relapse within 18 months (ER18) after initial treatment
Study: 37846935
Drug: High-Flow Nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Flow Nasal Oxygen (HFNO) treatment
Study: 37847131
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis (IVT) prior to endovascular thrombectomy (EVT)
Study: 37847131
Drug: Endovascular thrombectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular thrombectomy (EVT) without intravenous thrombolysis (IVT)
Study: 37847288
Drug: Hemp supplementation
Normalized name: hemp
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemp supplementation (60 g/d containing 40 g protein and 9 g oil)
Study: 37847288
Drug: Soy supplementation
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy supplementation (60 g/d matched for protein and calories)
Study: 37847317
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (4 g of omega-3 acid ethyl esters, Lovaza)
Study: 37847518
Drug: 100-µg mRNA-1273
Normalized name: MRNA-1273 SARS-COV-2
DrugBank: Moderna COVID-19 Vaccine (DB15654)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-µg mRNA-1273 (Moderna)
Study: 37847518
Drug: 30-µg BNT162b2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-µg BNT162b2 (Pfizer-BioNTech)
Study: 37847688
Drug: nintedanib 150
Normalized name: nintedanib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nintedanib 150 mg BID plus weekly docetaxel (35 mg/m2)
Study: 37847688
Drug: nintedanib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: nintedanib 200 mg BID plus weekly docetaxel (35 mg/m2)
Study: 37847761
Drug: Epirubicin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (mean dose of 304 mg/m²)
Study: 37847768
Drug: Other contemporary
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other contemporary therapies (primarily systemic thrombolysis and anticoagulation)
Study: 37848259
Drug: Cosibelimab 800
Normalized name: Cosibelimab
DrugBank: Cosibelimab (DB15770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cosibelimab 800 mg intravenously every 2 weeks
Study: 37848297
Drug: Pyrvinium pamoate
Normalized name: Pyrvinium Pamoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrvinium pamoate (PP) at 5 mg/kg orally for 3 days prior to surgery.
Study: 37848297
Drug: Pyrvinium pamoate
Normalized name: Pyrvinium Pamoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrvinium pamoate (PP) at 10 mg/kg orally for 3 days prior to surgery (if tolerated).
Study: 37848297
Drug: Pyrvinium pamoate
Normalized name: Pyrvinium Pamoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrvinium pamoate (PP) at 20 mg/kg orally for 3 days prior to surgery (if tolerated).
Study: 37848634
Drug: CS1-BCMA CAR-T
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS1-BCMA CAR-T infusion
Study: 37848887
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg immediate release methylphenidate (IR-MPH)
Study: 37848908
Drug: MyoCare ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: MyoCare ophthalmic lenses
Study: 37848908
Drug: Clearview ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clearview ophthalmic lenses
Study: 37849000
Drug: Transcutaneous auricular
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous auricular vagus nerve stimulation (ta-VNS) targeting the cymba conchae of the external left ear, 5 min duration once daily for 2 weeks, followed by crossover to sham stimulation for 2 weeks, then ta-VNS 5 min duration twice daily until week 16.
Study: 37849504
Drug: Clindamycin as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin as adjunctive therapy
Study: 37849628
Drug: Zagotenemab 70
Normalized name: Zagotenemab
DrugBank: Zagotenemab (DB16674)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zagotenemab 70 mg
Study: 37849628
Drug: Zagotenemab 210
Normalized name: Zagotenemab
DrugBank: Zagotenemab (DB16674)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zagotenemab 210 mg
Study: 37849628
Drug: Zagotenemab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zagotenemab (both doses)
Study: 37849833
Drug: Non-invasive neuromodulation-induced
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-invasive neuromodulation-induced cortical prehabilitation (NICP) protocol, involving 10 to 20 daily sessions of neuromodulation coupled with intensive task training.
Study: 37850197
Drug: App-delivered cognitive-behavioral
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: App-delivered cognitive-behavioral therapy for insomnia (CBT-I) adjunct to inpatient multimodal rehabilitation
Study: 37850330
Drug: Lidocaine and
Normalized name: Lidocaine and Tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine and ketamine infusions
Study: 37850379
Drug: Inclisiran sodium
Normalized name: inclisiran sodium
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inclisiran sodium 300 mg (equivalent to 284 mg of inclisiran)
Study: 37850941
Drug: Tubeless Automated
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tubeless Automated Insulin Delivery System
Study: 37851284
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula (HFNC) oxygen therapy for 1 hour
Study: 37851284
Drug: Standard oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oxygen therapy for 1 hour
Study: 37851297
Drug: Sotatercept plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotatercept plus background therapy (BGT)
Study: 37851336
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg oral eliapixant twice daily
Study: 37851412
Drug: HZ/su vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HZ/su vaccine (Shingrix)
Study: 37851412
Drug: HZ/su vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HZ/su vaccine (Shingrix) in patients receiving JAKi + methotrexate
Study: 37851500
Drug: Implementation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implementation of eHealth solutions
Study: 37851566
Drug: Dolutegravir 50
Normalized name: dolutegravir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 50 mg (DTG)
Study: 37851566
Drug: Low-dose Efavirenz
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Efavirenz (EFV400)
Study: 37851608
Drug: Single-dose rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single-dose rituximab plus glucocorticoid (methylprednisolone 0.8 mg/kg per day for the first 3 weeks and then tapered)
Study: 37851608
Drug: Cyclophosphamide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide plus glucocorticoid (methylprednisolone 0.8 mg/kg per day for the first 3 weeks and then tapered)
Study: 37851663
Drug: Flunarizine (12-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (12-week treatment)
Study: 37991122
Drug: New disabilities
Approvals — FDA: no, EMA: no, PMDA: no
Description: New disabilities in instrumental activities of daily living
Study: 37851874
Drug: Enzalutamide (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzalutamide (160 mg) daily plus leuprolide every 12 weeks (combination group)
Study: 37851874
Drug: Enzalutamide monotherapy
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide monotherapy (monotherapy group)
Study: 37852261
Drug: Cadonilimab 6
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab 6 mg/kg once every 2 weeks